A double-stapled peptide called FRNC-1 survived digestion and improved bone density when taken orally in mice — the first peptide shown to be orally effective for osteoporosis.
First oral peptideFRNC-1 is the first stapled peptide validated as orally effective for osteoporosis, working in mice via both injection and oral administration
What the researchers found
The double-stapled peptide FRNC-1 is the first orally effective peptide validated as a therapeutic candidate for postmenopausal osteoporosis. It inhibited bone resorption by mature osteoclasts through specific inhibition of phosphorylated GSK-3β, showed markedly improved helical content and proteolytic resistance compared to its linear form, and effectively prevented osteoclast activation and improved bone density in ovariectomized mice after both intravenous and oral (intragastric) administration.
Why it matters
Oral delivery of peptide drugs has been one of the biggest challenges in pharmaceutical development — most peptides are destroyed by stomach acid and digestive enzymes. Achieving oral efficacy with a stapled peptide for osteoporosis is a breakthrough that could transform how peptide drugs are administered, moving from injections to pills for a condition affecting hundreds of millions of postmenopausal women worldwide.
The numbers in context
Double-stapled peptide FRNC-1 · improved helical content vs linear form · effective via IV and oral routes · GSK-3β phosphorylation inhibition · improved bone density in OVX mice
How the study worked
Researchers designed and synthesized the double-stapled peptide FRNC-1 using all-hydrocarbon stapling. They characterized helical content and proteolytic stability compared to the linear form. In vitro, they tested FRNC-1's effect on mature osteoclast bone resorption and GSK-3β phosphorylation. In vivo, ovariectomized mice (a standard postmenopausal osteoporosis model) received FRNC-1 by both intravenous injection and oral (intragastric) administration, with bone density as the primary outcome.
Who was studied
Ovariectomized mice (postmenopausal osteoporosis model) and in vitro osteoclast cultures
What this study cannot tell us
Mouse model — ovariectomized mice don't fully replicate human postmenopausal osteoporosis. Oral bioavailability numbers, specific dosing, and treatment duration are not detailed in the abstract. Long-term safety, especially effects on non-bone tissues where GSK-3β is important, requires investigation. Human pharmacokinetics and efficacy studies are needed.
How to read the evidence
This is a preclinical proof-of-concept study demonstrating oral efficacy in mice. While the achievement of oral peptide delivery is significant, it represents early-stage evidence requiring pharmacokinetic characterization and human clinical testing.
When this study was published
Published in 2023, this represents the cutting edge of stapled peptide technology. The oral delivery achievement builds on a decade of advances in peptide stapling and could influence the direction of peptide drug development.
The bigger picture
Oral peptide delivery is considered a holy grail in drug development. Most peptide drugs — from insulin to GLP-1 agonists — require injection, limiting patient acceptance and adherence. FRNC-1 demonstrates that double-stapling technology can create peptides stable enough to survive the GI tract. If this approach generalizes, it could enable oral formulations for many peptide drugs currently limited to injection, fundamentally changing how peptide therapeutics are delivered.
Questions still open
- What is the actual oral bioavailability of FRNC-1, and how does it compare to injectable peptide osteoporosis drugs?
- Could this double-stapling approach be applied to other therapeutic peptides to create oral formulations?
- Would long-term oral FRNC-1 treatment produce sustained bone protection without off-target effects from GSK-3β inhibition?
Common questions
Why is it so hard to make peptide drugs that can be swallowed?
How does FRNC-1 strengthen bones?
Read the original research
Discovery of an orally effective double-stapled peptide for reducing ovariectomy-induced bone loss in mice.
Acta pharmaceutica Sinica. B, 13(9), 3770-3781
Citation
Cong, Wei; Shen, Huaxing; Liao, Xiufei; Zheng, Mengjun; Kong, Xianglong; Wang, Zhe; Chen, Si; Li, Yulei; Hu, Honggang; Li, Xiang. (2023). Discovery of an orally effective double-stapled peptide for reducing ovariectomy-induced bone loss in mice.. Acta pharmaceutica Sinica. B, 13(9), 3770-3781. https://doi.org/10.1016/j.apsb.2023.05.004